blood-brain barrier comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
=== Venezuela intervention === Several US B-52 Stratofortress long-range bombers flew from Minot Air Force Base in North Dakota within several miles of the coast of Venezuela on 20 November in what SOUTHCOM described as a "bomber attack demo". On 22 November, senior Trump administration officials told Reuters that the US was prepared to launch a new phase of operations against Venezuela. Dan Caine visited Puerto Rico as the "Trump Administration weigh[ed] the possibility of a broader military campaign against Venezuela". According to The New York Times, he was "expected to consult with commanders"; sources said that Trump had approved covert CIA activity in Venezuela, and authorized additional negotiations with Maduro, but had not yet authorized the use of land forces. The US began seizing, intercepting or pursuing tankers transporting Venezuelan oil on 11 December, and on 17 December, Trump ordered a "blockade" of sanctioned oil tankers heading to and from Venezuela. The first strike on a land target in Venezuela was announced by Trump on 26 December 2025—a marine facility the US said had been used for loading drug boats had been hit in a drone strike by the CIA, with no casualties, likely on 24 December. On 3 January 2026, explosions and low-flying aircraft were reported in Caracas and other locations and Maduro was captured in Operation Absolute Resolve by the US.
A set of NRPS enzymes (peptide synthase VpsA, VpsB, and VpsC) are responsible for assembling the heptapeptide. (Figure 2). VpsA codes for modules 1, 2, and 3. VpsB codes for modules 4, 5, and 6, and VpsC codes for module 7. The vancomycin aglycone contains 4 D-amino acids, although the NRPSs only contain 3 epimerization domains. The origin of D-Leu at residue 1 is unknown. The three peptide syntheses are at the start of the region of the bacterial genome linked with antibiotic biosynthesis, and span 27 kb. β-hydroxytyrosine (β-HT) is synthesized before incorporation into the heptapeptide backbone. L-tyrosine is activated and loaded on the NRPS VpsD, hydroxylated by OxyD, and released by the thioesterase Vhp. The timing of the chlorination by halogenase VhaA during biosynthesis is undetermined, but is proposed to occur before the complete assembly of the heptapeptide. After the linear heptapeptide molecule is synthesized, vancomycin must undergo further modifications, such as oxidative cross-linking and glycosylation, in trans by distinct enzymes, referred to as tailoring enzymes, to become biologically active (Figure 3). To convert the linear heptapeptide to cross-linked, glycosylated vancomycin, six enzymes are required. The enzymes OxyA, OxyB, OxyC, and OxyD are cytochrome P450 enzymes. OxyB catalyzes oxidative cross-linking between residues 4 and 6, OxyA between residues 2 and 4, and OxyC between residues 5 and 7. This cross-linking occurs while the heptapeptide is covalently bound to the PCP domain of the 7th NRPS module.
=== The pro-peptide === The MMPs are initially synthesized as inactive zymogens with a pro-peptide domain that must be removed before the enzyme is active. The pro-peptide domain is part of the "cysteine switch." This contains a conserved cysteine residue that interacts with the zinc in the active site and prevents binding and cleavage of the substrate, keeping the enzyme in an inactive form. In the majority of the MMPs, the cysteine residue is in the conserved sequence PRCGxPD. Some MMPs have a prohormone convertase cleavage site (Furin-like) as part of this domain, which, when cleaved, activates the enzyme. MMP-23A and MMP-23B include a transmembrane segment in this domain.
They called an ambulance which took him to Cedars-Sinai Medical Center, where Barker received stitches for an injured forehead and was released; he also hurt his left knee. Barker slipped and hit his head at home on June 19, 2017. His maid drove him to the emergency room, where Barker was checked and released. His representative said it was not as serious as his earlier fall. In October and November 2018, Barker was rushed to the hospital for severe back pain. Barker suffered another fall in January 2019, but he was not hospitalized. Barker's last public interview was with People in August 2021, in which he discussed The Price Is Right's upcoming 50th season on air. As of 2022, Burnet stated that, other than some non-prescription supplements such as collagen and a meal replacement drink to replenish nutrients not found naturally in Barker's vegetarian diet, he took only one prescription medication for hypothyroidism. On August 26, 2023, Barker died at his home in Los Angeles at the age of 99 of natural causes related to following several years fighting with Alzheimer's disease, a condition that Burnet and Barker's publicity team had kept hidden from the public. Hypertension, hyperlipidemia and hypothyroidism were listed as secondary causes of death. Barker was interred alongside his wife at Forest Lawn Memorial Park – Hollywood Hills.
== Related proteins == Fibronectin The second most abundant ECM molecule, this molecule also promotes homeostasis and maintaining the structure of the collagen matrix, as well as adhesion of cells to the matrix, and is created by hepatocytes. Some key differences include that fibronectin does not need a cartilage proteoglycan monomer to function efficiently, and is found at concentrations ten times higher than chondronectin in plasma. Also, instead of interacting with chondrocytes and type II collagen, fibronectins interact with other cells with types I and III collagen. Another difference is that fibronectin binds to the collagen directly before a cell can interact with the ECM. Laminin These glycoproteins also have a large molecular weight and are also trimeric in structure, like chondronectins. although they have 14 different combinations of trimer structures. Laminins facilitate the attachment of basement membranes in the human body, which are extracellular matrices that hold tissues and cells together. Laminins help to regulate cell activity, and have eleven distinct forms. Type II collagen A structural protein in the collagen matrix, type II collagen is much more abundant in the matrix than chondronectins, as this protein makes up 90-95% of the matrix. It is also found in the vitreous humor, and other areas of hyaline cartilage as well. Some key differences are that type II collagen is a structural protein that helps to provide structure and strength to the matrix, while chondronectins only facilitates binding of type II collagen to chondrocytes.
Sources: en.wikipedia.org
Papaver somniferum nothosubsp. authemaniiThis natural hybrid is native to France. It was first described as a hybrid named Papaver × authemanii in 1893 and reclassified to its accepted name in 2012. Papaver somniferum subsp. setigerumThis subspecies was first named Papaver setigerum in 1815 by Augustin Pyramus de Candolle. It was reclassified as a subspecies in 1882 by Giovanni Arcangeli. Its native range is North Africa from Morocco to Lybia and in southern Europe from Portugual to Italy. Papaver somniferum subsp. somniferum The autonymic subspecies is a cultigen, a plant that has been developed by human selection. The opium poppy has 76 synonyms of its two subspecies and the hybrid.
== External links == "Lurbinectedin". NCI Dictionary of Cancer Terms. National Cancer Institute. Clinical trial number NCT02454972 for "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors" at ClinicalTrials.gov
==== 5-HT system in vertebrates ==== Vertebrates are multicellular organisms in the phylum Chordata that possess a backbone and a nervous system. This includes mammals, fish, reptiles, birds, etc. In humans, the nervous system is composed of the central and peripheral nervous system, with little known about the specific mechanisms of neurotransmitters in most other vertebrates. However, it is known that while serotonin is involved in stress and behavioral responses, it is also important in cognitive functions. Brain organization in most vertebrates includes 5-HT cells in the hindbrain. In addition to this, 5-HT is often found in other sections of the brain in non-placental vertebrates, including the basal forebrain and pretectum. Since location of serotonin receptors contribute to behavioral responses, this suggests serotonin is part of specific pathways in non-placental vertebrates that are not present in amniotic organisms. Teleost fish and mice are organisms most often used to study the connection between serotonin and vertebrate behavior. Both organisms show similarities in the effect of serotonin on behavior, but differ in the mechanism in which the responses occur.
== Biomedical Science in the 20th century == At this point in history the field of medicine was the most prevalent sub field of biomedical science, as several breakthroughs on how to treat diseases and help the immune system were made. As well as the birth of body augmentations.
==== Electrochemical peptide biosensors ==== Electrochemical peptide biosensors measure the electrical signals generated when a target molecule interact with an immobilized peptide. This interaction alter charge transfer, variation in impedance, voltage, current or potential at the electrode interface. Due to its high sensitivity, it is widely employed for point-of-care and field applications.
Sources: en.wikipedia.org
Around 1862, Karl Heinrich Ritthausen isolated the amino acid glutamic acid. Thomas Burr Osborne compiled a detailed review of the vegetable proteins at the Connecticut Agricultural Experiment Station. Osborne, alongside Lafayette Mendel, established several nutritionally essential amino acids in feeding experiments with laboratory rats. Diets lacking an essential amino acid stunts the rats' growth, consistent with Liebig's law of the minimum. The final essential amino acid to be discovered, threonine, was identified by William Cumming Rose. The difficulty in purifying proteins impeded work by early protein biochemists. Proteins could be obtained in large quantities from blood, egg whites, and keratin, but individual proteins were unavailable. In the 1950s, the Armour Hot Dog Company purified 1 kg of bovine pancreatic ribonuclease A and made it freely available to scientists. This gesture helped ribonuclease A become a major target for biochemical study for the following decades.
Tapentadol was invented at the German pharmaceutical company Grünenthal in the late 1980s led by Helmut Buschmann; the team started by analyzing the chemistry and activity of tramadol, which had been invented at the same company in 1962. Tramadol has several enantiomers, and each forms metabolites after processing in the liver. These tramadol variants have varying activities at the μ-opioid receptor, the norepinephrine transporter, and the serotonin transporter, and differing half-lives, with the metabolites having the best activity. Using tramadol as a starting point, the team aimed to discover a single molecule that minimized the serotonin activity, had strong μ-opioid receptor agonism and strong norepinephrine reuptake inhibition, and would not require metabolism to be active; the result was tapentadol. In 2003 Grünenthal partnered with two Johnson & Johnson subsidiaries, Johnson & Johnson Pharmaceutical Research and Development and Ortho-McNeil Pharmaceutical to develop and market tapentadol; Johnson & Johnson had exclusive rights to sell the drug in the US, Canada, and Japan while Grünenthal retained rights elsewhere. In 2008 tapentadol received approval by the US Food and Drug Administration; in 2009 it was classified by US Drug Enforcement Agency as a Schedule II drug, and entered the US market. Tapentadol was reported to be the "first new molecular entity of oral centrally acting analgesics" class approved in the United States in more than 25 years. In 2010 Grünenthal granted Johnson & Johnson the right to market tapentadol in about 80 additional countries.
== Medical uses == Heartburn, acid indigestion, and sour stomach Treatment for gastric and duodenal ulcers Treatment for pathologic gastrointestinal hypersecretory conditions such as Zollinger–Ellison syndrome and multiple endocrine adenomas Treatment for gastroesophageal reflux disease (GERD) Treatment for esophagitis Part of a multidrug regimen for Helicobacter pylori eradication, although omeprazole may be somewhat more effective. Prevention of NSAID-induced peptic ulcers. Given to surgery patients before operations to reduce the risk of aspiration pneumonia.
18 June: The New Zealand Government announces the scrapping of the five-yearly national census. The Māori iwi (tribe) Te Patutokotoko files legal action against Conservation Minister Tama Potaka and the Department of Conservation for not consulting them about granting ten-year concessions to Whakapapa Holdings Limited and Pure Tūroa to run the Tūroa and Whakapapa skifields. New World's Victoria Park supermarket in Auckland is extensively damaged during a major fire. 19 June – The New Zealand Government confirms it suspended NZ$20 million of core sector support funding to the Cook Islands in early June 2025 in retaliation for the Cook Islands government signing a partnership agreement with China without consulting New Zealand, per the requirements of their free association relationship. 20 June Prime Minister Christopher Luxon meets with Chinese President Xi Jinping in Beijing to discuss strengthening bilateral tourism, education and agricultural trade. The New Zealand Symphony Orchestra announces simultaneously the scheduled conclusion of the tenure of Gemma New as its artistic director and principal conductor in 2027, and the appointment of André de Ridder as its new music director, effective in 2027. 21 June – Brian Tamaki's Destiny Church stages a march in Auckland's Aotea Square opposing the spread of non-Christian religions and immigration in New Zealand. Destiny Church's actions are denounced by Minister for Ethnic Communities Mark Mitchell.
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.